Controversies in Neurology THE 1ST REGIONAL UKRAINIAN CONGRESS CONTROVERSIES IN NEUROLOGY

November 23–24, 2017 Kyiv, Ukraine CONGRESS PROGRAM EACCME® event LEE17-00799 5. ВАРИАНТЫ БЛОКИРОВОК

5.1. Графическое изображение вариантов блокировок приведены на рис. 5.

Controversies in Neurology

Welcome to Kyiv, Welcome to the Ist Ukrainian Congress on Controversies in Neurology! We are proudly hosting this year the 1st Ukrainian Regional Con - gress on Controversies in Neurology – a unique science and educationРис. 5 event where physicians can meet world leading experts of major neurological fields and find out the new information on Дизайн-формация •МАЙСТЕРНЯ СК!ПА• the most nowadays issues. The unique format of the congress in the form of discussion and debates provides a platform for international experts to exchange and compare experience

We sincerely hope you’ll enjoy the Congress and beautiful city Kyiv!

Learn more: www.rimon.in.ua/cony/2017 www.ulae.org.ua

THE 1ST REGIONAL UKRAINIAN CONGRESS CONTROVERSIES IN NEUROLOGY Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

WELCOME address COMMITTEE

Dear Friends and Colleagues!

From the moment of its establishment in 2007, the World Congress has become a unique sci- International World Congress on Controversies in Neurology, ence and education event where physicians can meet world leading experts of major neu- Organising Prof. Amos D. Korczyn rological fields and find out the new information on the most nowadays issues. The unique format of the congress in the form of discussion and debates provides a platform for interna- committee tional experts to exchange and compare experience and it attracts attention of more and more specialists. The purpose of the Congress is to produce the most relevant clinical data and the latest scientific information, helping in every day patient care. Local The main topics that will be discussed at the First Regional Ukrainian Congress on Controver- SI “Institute of neurology, psychology and sies in Neurology are Epilepsy, Headache & pain, Neuropsychiatry & Behavioral Neurology, Organising Narcology NAMS Ukraine”, Parkinson’s disease & other movement disorders, Multiple sclerosis. The moderators of the committee Prof. Andriy Dubenko work sections of the congress will act together with leading Ukrainian specialists and interna- tional experts, who participated in world congresses of the same format. Uzhhorod National University, The multidisciplinary approach will offer the latest world-wide information, presented in a Prof. Volodymyr Smolanka unique format, for different specialists, such as neurologists, psychiatrists, family doctors and Ukrainian Association of others. Neuropsychopharmacology, We cordially invite all those who are interested to join this unique event. We are glad to wel- Prof. Volodymyr Korostiy come guests from all over Ukraine and foreign guests in the capital of Ukraine, Kyiv. We hope that an interesting scientific and practical program of Congress, along with communication Ukrainian League Against Epilepsy, with colleagues and acquaintance with a beautiful city, will remain in your memory for a Prof. Andriy Dubenko long time. We are waiting for a meeting with you at the 1st Ukrainian Regional Congress on Controver- Charitable Foundation Research Innovations sies in Neurology in Kyiv! in Medicine “RIMON”, Nataliya Pryanykova With best regards,

International Organising committee Local Organising committee

Prof. Amos D. Korczyn Prof. Volodymyr Smolanka Prof. Andriy Dubenko

Technical organizer Projects Inn, LLC http://projects-inn.com 4 5 Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

GENERAL INFORMATION LOCATION Kyiv, Ukraine WELCOME! DATES Dear Friends and Colleagues, November, 23-24 2017 We are proud to announce that the 1st Ukrainian Regional Congress on Controversies in Neurology will take place in Kyiv, Ukraine in November, 23-24 2017. CONGRESS VENUE Controversies in Neurology a unique educational congress where physicians can meet with PREMIER HOTEL RUS KYIV, 4 Hospitalna St., Ukraine, https://hotelrus.phnr.com/en outstanding experts in major neurological fields and can be updated on the most pressing clinical questions of the day. We provide a platform for international experts to discuss and TRANSPORTATION compare experiences, enable participants to discuss and debate unresolved issues with world Distance from the venue to: Boryspil International Airport – 40 km, Zhuliany Interna- leaders in the field. The Congress aims at providing the most available relevant data armoring the clinician with reliable, up-to-date scientific information, helping in everyday patients care. tional Airport – 14 km, Central Railway Station – 5 km, River Station – 5 km. In recent years our congresses involve more participants from different fields and various How to get here: regions. We are interested to develop the regional representation. With active endorsement Subway: nearest station – «Palats Sportu», green line and support from Ukrainian colleagues, we delighted to launch The 1st Ukrainian Regional Congress on Controversies in Neurology in Kyiv. REGISTRATION AND HOSPITALITY DESK For the 1st regional Ukrainian congress we selected the most current topics: Epilepsy, Head- Wednesday, November 22: 14.00-18.00 (Elite Hall, 2nd floor) ache & pain, Neuropsychiatry & Behavioral Neurology, Parkinson’s disease & other move- Thursday, November 23: 08.00-19.00 (Foyer 1st floor) ment disorders, Multiple sclerosis Friday, November, 24: 07.30-16.30 (Foyer 1st floor) There are a number of partnership opportunities available, including industry-sponsored activities. In addition, we would be happy to tailor a sponsorship package to your specific needs. LANGUAGE The official languages of the congress are English / Ukrainian. During the entire We cordially invite you to join us in the beautiful city Kyiv! work of the Congress, two-way simultaneous interpretation is provided. You can About Kyiv also make a report in Russian.

There are cities that symbolize a nation and Kyiv is one of them. Kyiv is the soul of Ukraine, playing SPEAKERS ROOM OPENING HOURS AT THE PREMIER HOTEL RUS (HALL ELITE) a key part in the past, present and future of this country. One of the most beautiful cities in the Thursday, November 23: 08.00-19.00 world, Kyiv is covered in a sea of greenery, which can be seen everywhere - in its many parks, Friday, November, 24: 08.00-14.00 boulevards and gardens. At every corner of every street you will find beautiful historic sites. Today we are witnessing a great time in Kyiv’s and in Ukraine’s history. With the population of EXHIBITION OPENING HOURS AT THE PREMIER HOTEL RUS (HALL ELITE) over three million, the same as Rome, Paris, and Madrid, changes are tak- Thursday, November 23: 08.00-19.00 ing place at an amazing pace. At the same time, Kyiv faces challenges that Friday, November, 24: 08.00-16.00 other modern European cities face as well LUNCHES & COFFEE BREAKS Lunch and Coffee will be served for registered participants according to the times listed in the timetable For more information on Kyiv, please visit Kyiv city guide http://www.inyourpocket.com/kyiv 6 7 Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

CME ACCREDITATION CME ACCREDITATION: 13 CREDIT POINTS! The 1st Regional Ukrainian Congress on Controversies in Neurology Kyiv, Ukraine, THE 1ST Regional Ukrainian Congress on Controversies in Neurology is accredited by the 23/11/2017-24/11/2017 has been accredited by the European Accreditation Council for European Accreaditation Council for Continuing Medical Education (EACCME) to provide Continuing Medical Education (EACCME®) for a maximum of 13 European CME credits the following CME activity for medical specialist. The EACCME is an institution of the Eu- (ECMEC®s) Each medical specialist should claim only those credits that he/she actually ropean Union of Medical Specialists (UEMS) spent in the educational activity

CERTIFICATE OF ATTENDENCE All registered participants will receive Certificate of attendance in congress kit

INTERNET There will be free Wifi in the public area of the PREMIER HOTEL RUS, and a complimentary charging stations for electronics

SMOKING POLICY In accordance with the policy of the congress, this is a non-smoking congress www.uems.net

SAFETY AND SECURITY Please do not leave any bags or other personal belongings unattended at any time, whether outside or inside the session/exhibition halls

PASSPORT AND VISA Visitors from EU, USA, Canada, Britain can enter the Ukraine without a visa. A valid pass- port is all you need to enter Ukraine. Other nationals are advised to contact the embassy to check visa requirements for Ukraine PROFESSIONAL CONGRESS ORGANIZER Information about visa requirements can be found on the World Travel Guide website: Charitable foundation Research Innovations in Medicine “RIMON” https://www.worldtravelguide.net/guides/europe/ukraine/ Velyka Zhytomirska st., 20, 9 fl., Business centre “Panorama”, Kyiv, Ukraine Tel/Fax: +38 044 537 5277, E-mail: [email protected] CURRENCY The local currency is the UAH ( ) ACCOMODATION PREMIER HOTEL RUS KYIV, 4 Hospitalna St., Ukraine Please do not hesitate to contact the Secretariat if you require any additional information https://hotelrus.phnr.com/en or assistance. Please address all correspondence to [email protected] For more information please visit www.rimon.in.ua

8 9 Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

INTERNATIONAL EXPERTS

Amos D. Korczyn Professor, Chairman of the Scientific Medical Board of the George Gegelashvili Doctor, Director, Georgian Institute of Health, President, (Tel Aviv, Israel) Israeli Alzheimer’s disease association (EMDA), member (Tbilisi, Georgia) Georgian Headache Society, Ex-Director World Health of the SAB of Alzheimer Disease International (ADI), Organization program «Drug Policy» (1999–2000), Neu- an honorary member of the neurological societies of Israel, rologist at the Ministry of Internal Affairs, senior specialist Serbia, Poland and Russia. (2001–2003)

Section: Section: PLENARY SESSION, HEADACHE & PAIN NEUROPHSYCHIATRY AND BEHAVIORAL NEUROLOGY

Aydin Gozalov Professor, Consultant Neurologist-Headache Specialist, Horst Przuntek Professor, Dr., Department of Neurologe, Ruhr University MD, PhD (Copenhagen, (Bochum, Germany) of Bochum Denmark) Danish Headache Center, Department of Neurology Glostrup Hospital, University of Copenhagen Section: PARKINSON’S DISEASE & MOVEMENT DISORDERS, Section: MULTIPLE SCLEROSIS HEADACHE & PAIN

Dimos-Dimitrios D. Associate Professor of Neurology, Aeginition Hospital, Ilan Blatt Professor, Past President of the International League Mitsikostas heading the Headache Unit, the MS Unit, The Clinical Trials (Ramat Gan, Israel) Against Epilepsy, Epilepsy Clinic, Dept. Of of Neurology at (Athens, Greece) Unit and the stroke Unit of the 1se Neurology Department. the Chaim Sheba Medical Center. President of the Hellenic Headache Society (2015–2018) Section: EPILEPSY Section: HEADACHE & PAIN

10 11 Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Jaime Kulisevsky MD, PhD, Scientific Director of Institut de Recerca Messoud Ashina Professor of Neurology & Chief Consultant, (Barcelona, Spain) (Barcelona) (Copenhagen, Director of the Human Migraine Research Unit Dr. Kulisevsky is Associate Professor of Neurology at the Denmark) Department of Neurology & Danish Headache Center, University of Barcelona (UB), Professor of Research at the Rigshospitalet Glostrup Open University of Catalonia (UOC) and Director of the Faculty of Health and Medical Sciences, Movement Disorders Unit at the HSCSP. University of Copenhagen

Section: Section: PARKINSON’S DISEASE & MOVEMENT DISORDERS HEADACHE & PAIN

Konrad Rejdak Professor, Department of Neurology, Morris Freedman Dr., Head of Neurology and Medical Director of Cognition (Warsaw, Poland) Medical University of Lublin & (Toronto, Canada) and Behaivors at Baycrest Centre for Geriatric Care Medical Research Center in Warsaw, Poland Section: Section: EPILEPSY NEUROPHSYCHIATRY AND BEHAVIORAL NEUROLOGY

Lars Bendtsen MD, PhD, Dr.Med.Sci (Copenhagen, Associate Professor at the Department of Neurology Denmark) and Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen.

Section: HEADACHE & PAIN

12 13 Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

CONGRESS TIMETABLE

Wednesday, November 22, 2017 HALL ELITE 2nd FLOOR 14:00–18:00 Registration 19:00 Welcome reception (Restaurant RUS 2ND FLOOR)

Thursday, November 23, 2017

Hall A Hall B+C+D Hall F Hall E 09:00–11:00 OPENING SESSION AND PLENARY LECTURES Chairs: Amos D. Korczyn, Israel & Volodymyr Smolanka, Ukraine 11:00–12:00 Coffee Break (HALL ELITE 2nd FLOOR) 12:00–14:00 MULTIPLE SCLEROSIS: NEUROPSYCHIATRY EPILEPSY CHANGES IN TREATMENT AND BEHAVIORAL NEUROLOGY Section heads: PARADIGM Section heads: Konrad Rejdak, Poland; Industry supported symposium Morris Freedman, Canada; Tetyana Litovchenko, Ukraine Supported by Roche Volodymyr Korostiy, Ukraine 14:00–15:00 Lunch Break (HALL ELITE 2nd FLOOR) 15:00–17:00 PARKINSON’S DISEASE & NEUROPSYCHIATRY MULTIPLE SCLEROSIS EPILEPSY MOVEMENT DISORDERS AND BEHAVIORAL NEUROLOGY Section head: Section heads: Section heads: Section heads: Tetyana Muratova, Ukraine Konrad Rejdak, Poland; Jaime Kulisevsky, Spain; Morris Freedman, Canada; Tetyana Litovchenko, Ukraine Tetyana Slobodin, Ukraine Volodymyr Korostiy, Ukraine 17:00–17:15 Coffee Break (HALL ELITE 2nd FLOOR) 17:15–19:15 PARKINSON’S DISEASE & NEUROPSYCHIATRY MULTIPLE SCLEROSIS MOVEMENT DISORDERS AND BEHAVIORAL NEUROLOGY Section head: Section heads: Section heads: Tetyana Muratova, Ukraine Jaime Kulisevsky, Spain; Morris Freedman, Canada; Tetyana Slobodin, Ukraine Volodymyr Korostiy, Ukraine

14 15 Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Friday, November 24, 2017 HALL VENICE 2nd FLOOR 08:00–09:00 Meet the expert Breakfast session Supported by Sanofi Genzyme

TREATABLE NEUROMUSCULAR DISEASES. POMPE DISEASE. Prof. Andoni Urtizberea, France

Hall A Hall B+C+D Hall F Hall E

09:00–11:00 HEADACHE & PAIN EPILEPSY MULTIPLE SCLEROSIS Section heads: Section heads: Section head: Messoud Ashina, Denmark; Konrad Rejdak, Poland; Tetyana Muratova, Ukraine Mikhaylo Oros, Ukraine Tetyana Litovchenko, Ukraine

11:00–11:30 Coffee Break (HALL ELITE 2nd FLOOR)

11:30–13:30 HEADACHE & PAIN PARKINSON’S DISEASE & MULTIPLE SCLEROSIS YOUNG INVESTIGATOR Section heads: MOVEMENT DISORDERS Section head: SCHOLARSHIP Messoud Ashina, Denmark; Section heads: Tetyana Muratova, Ukraine Section head: Mikhaylo Oros, Ukraine Jaime Kulisevsky, Spain; Natalia Kufterina, Ukraine Tetyana Slobodin, Ukraine

13:30–14:30 Lunch Break (HALL ELITE 2nd FLOOR)

14:30–16:30 HEADACHE & PAIN Section heads: Messoud Ashina, Denmark; Mikhaylo Oros, Ukraine

16:30 CLOSING CEREMONY

16 17 THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine Controversies FLOORPLAN PREMIER HOTEL RUS KYIV in Neurology

Hall Hall F Hall E Hall A B+C+D Конференц-сервис 2017

1st floor registration

PROGRAM BY SECTIONS

Hall Rus Hall Venice

Hall Kiev elevators

Hall Elite

exhibition 2nd floor

18 19 THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Wednesday, November 22, 2017 PRECONGRESS DAY

HALL ELITE 2nd FLOOR 14:00–18:00 Registration 19:00 Welcome reception (Restaurant RUS 2nd FLOOR)

Thursday, November 23, 2017 PLENARY SESSION

Hall A 09:00–11:00 OPENING SESSION AND PLENARY LECTURES CHAIRS: Amos D. Korczyn, Israel, Volodymyr Smolanka, Ukraine, Andriy Dubenko, Ukraine 09:00–09:30 Welcome remarks and invitation to the 1st Regional Ukrainian Congress on Controversies in Neurology in Kyiv Andriy Dubenko, Ukraine, Amos D. Korczyn, Israel 09:30–10:00 Plenary lecture Are «functional» neurological diseases really psychogenic?» Amos D. Korczyn, Israel 10:00–10:30 Plenary lecture «Minor Strokes» – Big Problems Tamara Mishchenko, Ukraine 10:30–11:00 Plenary lecture Paraneoplastic syndromes in neurology practice Eugen Dubenko, Ukraine; Dmytro Kovalenko, Ukraine HALL ELITE 2nd FLOOR 11:00–12:00 Coffee Break

20 21 EPILEPSY EPILEPSY

Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Thursday, November 23, 2017 HALL ELITE 2nd FLOOR 14:00–15:00 Lunch Break Hall E Hall E CHAIRS: CHAIRS: Lidiya Maryenko, Ukraine; Valeriy Kalashnikov, Ukraine; Volodymyr Kharytonov, Ukraine Natalia Kufterina, Ukraine 12:00–13:00 Debate: 15:00–16:00 Debate: Are generics equally effective and safe as original AEDs Are new generation AEDs superior to the classical antiepileptic drugs in the management of epilepsy? Capsule: Generics used extensively in different countries. For pa- tients with epilepsy, the rules for using generic drugs have their Capsule: Over the past 30 years, the number of AED has increased own requirements. more than 3-fold. Many of them have been clinically tested as first- line therapy. However, the proportion of pharmacoresistant pa- 12:00–12:10 Debate host: Ilan Blatt, Israel tients remains the same. Is it appropriate to designate «new» AED? 12:10–12:25 YES: Taras Studenyak, Ukraine 15:00–15:10 Debate host: Lidiya Maryenko, Ukraine YES: Ilan Blatt, Israel 12:25–12:40 NO: Ludmila Tantsura, Ukraine 15:10–15:25 15:25–15:40 NO: Yurii Horansky, Ukraine 12:40–13:00 Discussion and rebuttals 15:40–16:00 Discussion and rebuttals 13:00–14:00 Debate: Debate: Whether VNS therapy is alternative to other methods of surgical 16:00–17:00 Should we always initiate treatment after first ever epileptic seizure? treatment in pharmacoresistant epilepsy? Capsule: According to the new definition of epilepsy, the diagnosis of Capsule: About 30% of patients epilepsy is remained resistant epilepsy is always needed after 2 unprovoked seizures. In what cases is to therapy. Application of VNS and other surgical methods in a it possible to diagnose epilepsy and start treatment after a first seizure? number of cases allows to overcome resistance. Whether can replace application of VNS other methods of surgical treatment 16:00–16:10 Debate host: Tetyana Litovchenko, Ukraine PRO: Konrad Rejdak, Poland 13:00–13:10 Debate host: Konrad Rejdak, Poland 16:10–16:25 16:25–16:40 CON: Volodymyr Kharytonov, Ukraine 13:10–13:25 PRO: Oleksander Dukhovsky, Ukraine 16:40–17:00 Discussion and rebuttals 13:25–13:40 CON: Kostyantyn Kostyuk, Ukraine HALL ELITE 2nd FLOOR 13:40–14:00 Discussion and rebuttals 17:00–17:15 Coffee Break

24 25 EPILEPSY

Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Friday, November 24, 2017

Hall B+C+D CHAIRS: Tetyana Litovchenko, Ukraine; Volodymyr Korostiy, Ukraine 09:00–10:00 Debate: The controversies of post-stroke epilepsy: diagnosis and clinical guidance Capsule: Should we consider the first attack of post-stroke seizures as a debut of epilepsy? When should we start administration of antiepileptic drugs and what medication should be chosen? 09:00–09:10 Debate host: Konrad Rejdak, Poland 09:10–09:25 PRO: Yuriy Vorokhta, Ukraine 09:25–09:40 CON: Denys Khramtsov, Ukraine 09:40–10:00 Discussion and rebuttals 10:00–11:00 Debate: Tactics of delivery in women with epilepsy: do all women with epilepsy need operative delivery? Capsule: Epileptic seizures increase the risk of infant and maternal mortality. Many clinicians consider surgical delivery necessary. How expedient surgical delivery for all women with epilepsy? 10:00–10:10 Debate host: Yurii Horansky, Ukraine 10:10–10:25 PRO: Andriy Dubenko, Ukraine 10:25–10:40 CON: Lidya Maryenko, Ukraine 10:40–11:00 Discussion and rebuttals HALL ELITE 2nd FLOOR 11:00–11:30 Coffee Break

26 27 PARKINSON’S DISEASE AND OTHER MOVEMENT DISORDERS PARKINSON’S DISEASE AND OTHER MOVEMENT DISORDERS Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Thursday, November 23, 2017

Horst Przuntek, Hall A 16:00–16:10 Debate host: Germany CHAIRS: 16:10–16:25 PRO: Tetyana Slobodin, Ukraine Tetyana Slobodin, Ukraine; Olena Krypchak, Ukraine 16:25–16:40 CON: Jaime Kulisevsky, Spain 15:00–16:00 Debate: 16:40–17:00 Discussion and rebuttals PD with dementia and dementia with Lewy bodies – one or two separate disorders? HALL ELITE 2nd FLOOR Capsule: DLB and PDD are important and common dementia syn- 17:00–17:15 Coffee Break dromes that overlap in their clinical features, neuropathology, and Hall A management. They are believed to exist on a spectrum of Lewy body disease.The distinction between these syndromes continues CHAIRS: to be an active clinical and research question. Olga Dubenko, Ukraine; 15:00–15:10 Debate host: Jaime Kulisevsky, Spain Yulia Neryanova, Ukraine 15:10–15:25 PRO: Yanosh Sanotsky, Ukraine 17:15–18:15 Debate: Is the development of clinically significant autonomic disorders an CON: Nataliya Pavlyshyna, Ukraine 15:25–15:40 undeniable sign of multisystem atrophy? 15:40–16:00 Discussion and rebuttals Capsule: In up to 50% of patients with MSA severe autonomic ab- CHAIRS: normalities, most frequently OH and erectile dysfunction, precede the Alla Cherkez, Ukraine; development of the movement disorder. Resent studies suggest that Olga Bordyzhenko, Ukraine peripheral postganglionic sympathetic denervation may occur earlier 16:00–17:00 Debate: in PD, thus constituting the earliest stage of the disease, at least Depression in PD is pathogenetically associated with the risk of de- in certain patients. Is the autonomic dysfunction a reliable clinical veloping impulsive-compulsive disorders marker of MSA, taking into account that MSA shares OH with PD and other neurodegenerative diseases with dementia? Capsule: ICD’s are especially seen in PD patients with young age of onset, higher doses of antiparkinsonian drugs, pre-existent or 17:15–17:25 Debate host: Oleksander Kalbus, Ukraine current depression, pre-existing recreational drug or alcohol use, 17:25–17:40 YES: Kateryna Karpynska, Ukraine and high novelty seeking personality traits. Is it worth to provide a detailed behavioral assessment, especially testing for depres- 17:40–17:55 NO: Gennadiy Moskovko, Ukraine sion before starting dopaminergic therapy, taking into account a relationship between impulsivity and depression? 17:55–18:15 Discussion and rebuttals

30 31 PARKINSON’S DISEASE AND OTHER MOVEMENT DISORDERS Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Friday, November 24, 2017 CHAIRS: Hall B+C+D Gennadiy Moskovko, Ukraine CHAIRS: Andriy Popov, Ukraine; Debate: 18:15–19:15 Maryanna Slychko, Ukraine Do we have 2017 a paradigma change in the treatment of PD consid- ering the microbiom pathology? 11:30–12:30 Debate: Are neuropsychiatric complications after DBS in patients with Capsule: The GIT could represent a vulnerable area through which Parkinson’s disease predictable? pathogens could induce CNS neuro-inflammation via microglia Capsule: Nowadays, the main surgical treatment for Parkinson disease, activation. Recent concepts may suggest the modulation of the dystonia, tics is deep brain stimulation (DBS), which has been reported to gut microbiota is an achievable strategy for innovative therapies have consequences such as decline in verbal fluency, episodes of depres- in neurodegenerative disorders, PD in particular sion, elevated incidences of suicide, hypomania, severe and lasting behavior disturbances, which were credibly not present in the preoperative phase. 18:15–18:25 Debate host: Tetyana Slobodin, Ukraine Could we suspect these these side effects before the operation? 11:30–11:40 Debate host: Irina Karaban, Ukraine 18:25–18:40 YES: Horst Przuntek, Germany 11:40–11:55 PRO: Kostyantyn Kostyuk, Ukraine 18:40–18:55 NO: Dmytro Maltsev, Ukraine 11:55–12:10 CON: Iryna Bogdanova, Ukraine 18:55–19:15 Discussion and rebuttals 12:10–12:30 Discussion and rebuttals CHAIRS: Alla Cherkez, Ukraine; Olena Krypchak, Ukraine 12:30–13:30 Debate: Whether vascular PD is a separate disease? Capsule: Currently, Parkinson’s disease (PD) and vascular parkinsonism (VP) can be considered as a different disease or is a consequence of cere- brovascular pathology? Can cerebrovascular diseases be considered the basis for the development of Parkinson’s disease? Cerebrovascular disease can be combined with Parkinson’s disease, what is the tactic of pathogenetic therapy in this cases? 12:30–12:40 Debate host: Gennadiy Moskovko, Ukraine 12:40–12:55 YES: Iryna Karaban, Ukraine 12:55–13:10 NO: Iryna Bogdanova, Ukraine 13:10–13:30 Discussion and rebuttals HALL ELITE 2nd FLOOR 13:30–14:30 Lunch Break

32 33 MULTIPLE SCLEROSIS MULTIPLE SCLEROSIS

Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Thursday, November 23, 2017

Hall F CHAIRS: 16:00–16:10 Debate host: Natalia Voloshina, Ukraine Tetyana Muratova, Ukraine 16:10–16:25 PRO: Tetyana Nehrych, Ukraine 15:00–16:00 Debate: There is a link between a deficiency in the body of vitamin D and the 16:25–16:40 CON: Olga Shulga, Ukraine onset of MS. Do we need to include, vitamin D as an adjunctive therapy? 16:40–17:00 Discussion and rebuttals Capsule: Vitamin D insufficiency considered to be a modifiable risk fac- tor for MS onset. About 1 billion people around the world have vitamin D HALL ELITE 2nd FLOOR deficiency or insufficiency. Can we recommend to patients with multiple 17:00–17:15 Coffee Break sclerosis to use nutritional supplements with vitamin D for treatment? CHAIRS: 15:00–15:10 Debate host: Olga Shulga, Ukraine Valeryi Pashkovsky, Ukraine

15:10–15:25 YES: Larysa Sokolova, Ukraine 17:15–18:15 Debate: Primary-progredient MS is a type of flow or an individual disease? 15:25–15:40 NO: Valeryi Pashkovsky, Ukraine Capsule: 15% of MS patients have a progressive form at disease 15:40–16:00 Discussion and rebuttals with gradual worsening of neurological status for at least 1 year. Diagnosis of primary progredient MS is a challenge and some 16:00–17:00 Debate: authors consider that it is an individual nosology or even the What are the priorities today in the treatment of MS - Anti-B-cell same disease with secondary progressive MS. Should we revise or nonspecific anti-B + T-therapy? classification of MS?

Capsule: Earlier concepts focused mainly on T-lymphocytes as 17:15–17:25 Debate host: Olena Myalovytska, Ukraine the key cell type to mediate inflammatory damage within CNS lesions, emerging evidence suggests that B lymphocytes may 17:25–17:40 PRO: Larysa Sokolova, Ukraine play an important role both as the precursors of antibody se- creting cells and as antigen presenting cells for the activation of 17:40–17:55 CON: Olena Tsurkalenko, Ukraine T-cells. What should be our target? Specific anti-B-cells therapy or non-specific anti-B+T-therapy is our priority? 17:55–18:15 Discussion and rebuttals

36 37 MULTIPLE SCLEROSIS

Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Friday, November 24, 2017 Hall F CHAIRS: 10:00–10:10 Debate host: Larysa Sokolova, Ukraine Tetyana Nehrych, Ukraine 10:10–10:25 PRO: Olena Tsurkalenko, Ukraine 09:00–10:00 Debate: CON: Horst Przuntek, Germany Acute demyelinating encephalomyelitis (ADEM) – if this is clinical form 10:25–10:40 of multiple sclerosis or various disease? Whether it is necessary to ap- 10:40–11:00 Discussion and rebuttals point or nominate modifying therapy at ADEM? HALL ELITE 2nd FLOOR Capsule: Acute disseminated ebcephalomyelitis (ADEM) is an 11:00–11:30 Coffee Break immune-mediated inflammatory demyelinating condition that predominately affects white matter of the brain and spinal cord. Hall F The division between MS and ADEM is indistinct suggesting CHAIRS: clinical continuum. Could we consider that ADEM is just a form of Tetyana Muratova, Ukraine MS? Could we prescrive any modyfying therapy at ADEM? Debate: 09:00–09:10 Debate host: Tetyana Nehrych, Ukraine 11:30–12:30 Can we prescribe/continue modifying therapy during pregnancy? What 09:10–09:25 PRO: Tetyana Muratova, Ukraine drugs should we prefer? 09:25–09:40 CON: Tetiana Kobys, Ukraine Capsule: MS is more prevalent in women of reproductive 09:40–10:00 Discussion and rebuttals age than in any other population group. There is no evidence that MS impairs fertility or leads to an increased number of 10:00–11:00 Debate: spontaneous abortions, stillbirths or congenital malformations. Should the modifying therapy be discontinued at the signs of secondary Several studies of large numbers of women have repeatedly progression and when? demonstrated that pregnancy, labor, delivery and the incidence Capsule: About 70% of patients with relapsing-remitting multiple sclerosis of fetal complications are no different in women who have MS (RRMS) develop secondary progressive multiple sclerosis (SPMS) for than in control groups without the disease. However there are 15–20 years of the disease, and in 25 years – 90%. The exact role of no evidence of the necessity of MT during pregnancy as well as modifying the disease in delaying this transition remains unclear. Does about the choice of MSMT. the main dilemma facing doctors make sense to continue to treat drugs 11:30–11:40 Debate host: Tetyana Muratova, Ukraine that are effective in relapsing-remitting multiple sclerosis, as the disease progresses to the secondary progressive MS. In the treatment of SPMS, 11:40–11:55 PRO: Natalia Voloshina, Ukraine this treatment seems to be losing its benefits, and since it often involves 11:55–12:10 CON: Tetyana Nehrych, Ukraine serious side effects and high costs, the clinicians have to decide whether to stop the treatment and when to do it? 12:10–12:30 Discussion and rebuttals

38 39 ®

1 in 3 Patients will not Respond ® Adequately to Anti-Epileptic Drugs

NEUROPSYCHIATRY AND BEHAVIORAL NEUROLOGY

VNS Therapy® - is an implantable medical device for Drug-Resistant Epilepsy (DRE)

VNS Therapy is an easy to use treatment that controls seizures by sending mild pulses from the generator to the left vagus nerve at regular intervals all day, every day. To discover how VNS Therapy Can be safely be used as an adjunctive treatment, offering proven could help your DRE Patients therapeutic outcomes. visit www.vnstherapy.com

VNS = Vagus Nerve Stimulation

AspireSR® is CE mark approved and commercial distribution may vary by country. cardiac, or respiratory difficulties (including, but not limited to, obstructive sleep apnea and chronic pulmonary disease) should discuss with their physicians whether VNS Therapy is appropriate for them VNS THERAPY EUROPEAN INDICATION FOR USE VNS Therapy is indicated for use as an adjunctive therapy in reducing the frequency of seizures since there is the possibility that stimulation might worsen their condition. Postoperative bradycardia in patients whose epileptic disorder is dominated by partial seizures (with or without secondary can occur among patients with certain underlying cardiac arrhythmias. MRI can be safely performed; generalization) or generalized seizures that are refractory to seizure medications. The Model 106 however, special equipment and procedures must be used. AspireSR® (Seizure Response) features the Automatic Stimulation Mode, which is intended for patients ADVERSE EVENTS: The most commonly reported side effects from stimulation include hoarseness (voice who experience seizures that are associated with cardiac rhythm increases known as ictal tachycardia. alteration), paresthesia (prickling feeling in the skin), dyspnea (shortness of breath), sore throat and CONTRAINDICATIONS: The VNS Therapy system cannot be used in patients after a bilateral or left increased coughing. The most commonly reported side effect from the implant procedure is infection. cervical vagotomy. Do not use short-wave diathermy, microwave diathermy, or therapeutic ultrasound *The information contained here represents partial excerpts of important prescribing information diathermy on patients implanted with the VNS Therapy system. Diagnostic ultrasound is not included from the product labeling. Patients should discuss the risks and benefits of VNS Therapy with their in this contraindication. Cardiac arrhythmia (Model 106 only)—The AutoStim Mode feature should not healthcare provider. Visit www.VNSTherapy.com for more information. be used in patients with clinically meaningful arrhythmias or who are using treatments that interfere OUSADBS15-11-1000-EEA with normal intrinsic heart rate responses. WARNINGS: Physicians should inform patients about all potential risks and adverse events discussed CYBERONICS EUROPE BVBA in the VNS Therapy Physician Manuals, including information that VNS Therapy may not be a cure for WHOLLY-OWNED SUBSIDIARY OF LIVANOVA PLC 100 Cyberonics Boulevard epilepsy. Since seizures may occur unexpectedly, patients should consult with a physician before Airport Plaza Houston, Texas 77058 engaging in unsupervised activities, such as driving, swimming, and bathing, or in strenuous sports Kyoto Building Tel: +1.800.332.1375 that could harm them or others. A malfunction of the VNS Therapy system could cause painful or Leonardo Da Vincilaan 19 Fax: +1.281.218.9332 direct current stimulation, which could result in nerve damage. Removal or replacement of the VNS B-1831 Diegem, Belgium Therapy system requires an additional surgical procedure. Patients who have pre-existing swallowing, Tel: +32.2.720.95.93 Fax: +32.2.720.60.53

2016 Cyberonics Inc, a wholly-owned subsidiary of LivaNova PLC. All rights reserved. Cyberonics® and VNS Therapy® are registered trademarks of Cyberonics, Inc. EANAd16E1

Aspire A4 advert - Final.indd 1 27/05/2016 09:36 NEUROPSYCHIATRY AND BEHAVIORAL NEUROLOGY Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine Thursday, November 23, 2017 Hall B+C+D Hall B+C+D CHAIRS: CHAIRS: Morris Freedman, Canada; Horst Przuntek, Germany; Mikhaylo Oros, Ukraine Tetyana Slobodin, Ukraine 15:00–16:00 Debate: Is it relevant to use VNS therapy in depression? 12:00–13:00 Debate: Capsule: Vagus nerve stimulation (VNS) was approved by the FDA Does Bilingualism Delay the Onset of Alzheimer’s Disease for the treatment of severe, recurrent unipolar and bipolar depression Capsule: There is evidence that speaking more than one language in July of 2005. But, VNS is not a rapid treatment for depression: delays the onset of dementia but this is not universally accepted studies show that, on average, it may take up to 9 months for a treatment response to occur 12:00–12:10 Debate host: Nina Sofilkanych, Ukraine 15:00–15:10 Debate host: Kostyantyn Kostyuk, Ukraine 12:10–12:25 PRO: Morris Freedman, Canada 15:10–15:25 PRO: Volodymyr Korostiy, Ukraine 12:25–12:40 CON: Andriy Dubenko, Ukraine 15:25–15:40 CON: Olga Mostova, Ukraine 12:40–13:00 Discussion and rebuttals 15:40–16:00 Discussion and rebuttals 13:00–14:00 Debate: Is mild cognitive impairment (MCI) a useful concept? 16:00–17:00 Debate: Is beta-amyloid still a relevant target in AD therapy? Capsule: Within the framework of AD, preclinical cognitive Capsule: Accumulation of type 2 beta-amyloid is a proven link impairment is usually captured using the term MCI. Do we need in the pathogenesis of AD, but today there have been other this term? hypotheses that may be more promising in terms of treating AD 13:00–13:10 Debate host: Olga Mostova, Ukraine 16:00–16:10 Debate host: Volodymyr Korostiy, Ukraine 13:10–13:25 PRO: Volodymyr Korostiy, Ukraine 16:10–16:25 YES: Nina Sofilkanych, Ukraine 13:25–13:40 CON: Morris Freedman, Canada 16:25–16:40 NO: Amos D. Korсzyn, Israel 13:40–14:00 Discussion and rebuttals 16:40–17:00 Discussion and rebuttals HALL ELITE 2nd FLOOR HALL ELITE 2nd FLOOR 14:00–15:00 Lunch Break 17:00–17:15 Coffee Break

42 43 NEUROPSYCHIATRY AND BEHAVIORAL NEUROLOGY Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Hall B+C+D CHAIRS: Morris Freedman, Canada; Volodymyr Kharytonov, Ukraine 17:15–18:15 Debate: Is AD a non-specific manifestation of aging? Capsule: AD is a disease that can occur in any person if you live long enough 17:15–17:25 Debate host: Andriy Dubenko, Ukraine 17:25–17:40 PRO: Amos D. Korсzyn, Israel 17:40–17:55 CON: Volodymyr Korostiy, Ukraine 17:55–18:15 Discussion and rebuttals 18:15–19:15 Debate: Does depression contribute to dementia? Capsule: «Cold» violations of cognitive functions in depression & affective disorders of cognitive functions in dementia - pathogenetic affinity or comorbidity? 18:15–18:25 Debate host: Nina Sofilkanych, Ukraine 18:25–18:40 PRO: Olga Mostova, Ukraine 18:40–18:55 CON: Volodymyr Korostiy, Ukraine 18:55–19:15 Discussion and rebuttals

44 45 HEADACHE & PAIN HEADACHE & PAIN

Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Friday, November 24, 2017 Hall A Hall A CHAIRS: CHAIRS: Mikhaylo Oros, Ukraine; Mikhaylo Oros, Ukraine; Messoud Ashina, Denmark Messoud Ashina, Denmark 09:00–10:00 Debate: Can response to triptan be used to diagnose migraine? 11:30–12:30 Debate: Capsule: No specific diagnostic test is available to diagnose Antidepressant medications are effective in migraine primary headaches. Triptans are selective serotonin receptor agonists developed to treat migraine. Can triptans be used to Capsule: Epidemiological have shown that migraine is comorbid treat other pirmary headaches? Can we use triptan response to with depression. Antidepressants are often prescribed for diagnose migraine? migraines. Can antidepressants prevent and treat headaches? 09:00–09:10 Debate host: Igor Romanenko, Ukraine 11:30–11:40 Debate host: Igor Romanenko, Ukraine 09:10–09:25 PRO: George Gegelashvili, Georgia 11:40–11:55 YES: Dimos Mitsikostas, Greece 09:25–09:40 CON: Messoud Ashina, Denmark 11:55–12:10 NO: Lars Bendtsen, Denmark 09:40–10:00 Discussion and rebuttals 10:00–11:00 Debate: 12:10–12:30 Discussion and rebuttals Microvascular decompression should be considered as first line ap- 12:30–13:30 Debate: proach in trigeminal neuralgia Multiple-drug combinations are effective in migraine and cluster Capsule: Trigeminal neuralgia treatment usually starts with headache preventive medications. Pharmacological treatment is often Capsule: Should we use combined treatment in clinical practice? associated with intolerable and numerous adverse effects. Some headache experts recommend to combine multiple Microvascular decompression (MVD), also known as the Jannetta drug combinations for migraine and cluster headache. Is there procedure, is a neurosurgical procedure to treat trigeminal sufficient evidence to support combined treatment? neuralgia. Should MVD be considered as first line approach in managment of trigeminal neuralgia? 12:30–12:40 Debate host: Valeriy Kalashnikov, Ukraine 10:00–10:10 Debate host: Volodymyr Smolanka, Ukraine 12:40–12:55 PRO: Lars Bendtsen, Denmark 10:10–10:25 PRO: George Gegelashvili, Georgia 12:55–13:10 CON: Mikhaylo Oros, Ukraine 10:25–10:40 CON: Aydin Gozalov, Denmark 10:40–11:00 Discussion and rebuttals 13:10–13:30 Discussion and rebuttals Hall ELITE 2nd floor Hall ELITE 2nd floor 11:00–11:30 Coffee Break 13:30–14:30 Lunch Break

48 49 HEADACHE & PAIN

Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Hall A CHAIRS: George Gegelashvili, Georgia; Volodymyr Romanenko, Ukraine 14:30–15:30 Debate: Migraine and tension-type headache is the same disorder Capsule: Tension-type headache is the most common headache type in the world. Some patients describe a daily tension-type headache as well as a recurrent migraine attacks. Should these patients be diagnosed as coexisting migraine and tension-type headache? Or is migraine and tension-type headache the same disorder? 14:30–14:40 Debate host: Natalia Kufterina, Ukraine 14:40–14:55 PRO: Volodymyr Romanenko, Ukraine 14:55–15:10 CON: Messoud Ashina, Denmark 15:10–15:30 Discussion and rebuttals 15:30–16:30 Debate: Persistent idiopathic facial pain is a manifestation of somatoform disorder Capsule: The issue of manifestation of somatoform pain syndrome has existed for more than 150 years, but has not been resolved to this day. Is there an organic substrate of idiopathic pain in the face or not? 15:30–15:40 Debate host: Volodymyr Korostiy, Ukraine 15:40–15:55 YES: Dimos Mitsikostas, Greece 15:55–16:10 NO: Aydin Gozalov, Denmark 16:10–16:30 Discussion and rebuttals 16:30 CLOSING CEREMONY

50 51 INDUSTRY SUPPORTED SYMPOSIUM Controversies SUPPORTED BY ROCHE in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Thursday, November 23, 2017

Hall A CHAIRS: Tetyana Nehrych, Ukraine

12:00–13:30 Multiple sclerosis: change in treatment paradigm Industry supported symposium Non-CME session, Supported by Roche

12:00–12:10 Introduction

12:10–12:30 A new concept in the pathogenesis of multiple sclerosis – key role of B cells Tetyana Nehrych, Ukraine

12:30–12:50 Progress in diagnostics and monitoring of multiple sclerosis course Larysa Sokolova, Ukraine

12:50–13:10 Ocrelizumab – from clinical trials to the practical using Natalia Voloshina, Ukraine

13:10–13:30 Questions & Answers. Discussion HALL ELITE 2nd FLOOR 14:00–15:00 Lunch Break

52 53 MEET THE EXPERT SESSION

Controversies SUPPORTED BY SANOFI GENZYME in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

Friday, November 24, 2017

BREAKFAST WITH EXPERT

Hall VENICE 2nd floor 08:00–09:00 Breakfast with expert

Meet the expert session TREATABLE NEUROMUSCULAR DISEASES. POMPE DISEASE. Non-CME session, Supported by Sanofi Genzyme Prof. Andoni Urtizberea, France

54 55 Controversies in Neurology November 23–24, 2017 Kyiv, Ukraine Friday, November 24, 2017 YOUNG INVESTIGATION SCHOLARSHIP

Hall E CHAIRS: Natalia Kufterina, Ukraine Andriy Dubenko, Ukraine 11:30–12:30 YOUNG INVESTIGATOR SCHOLARSHIP oral and visual presentations 11:30–11:35 Introduction 11:35–11:40 Frequency of status epilepticus in women with epilepsy Abramov, H. Odintsova, Ulytyn, Saint Petersburg, Russia 11:40–11:45 Characteristics of Multiple sclerosis relapses and factors affecting relapses frequency in patients with immunolodulatory therapy Myroslav Bozhenko, Olga Shulga, Lutsk, Ukraine 11:45–11:50 Importance of EEG-video monitoring for differential diagnosis of epileptic and non-epileptic peroxysmal states Anna Voitiuk, Kharkiv, Ukraine 11:50–11:55 Cardiovascular effects of antiepileptic drugs Valeriya Grymaylo, Kharkiv, Ukraine 11:55–12:00 Detection of neuro-psychiatric disorders among medical students Anastasiya Makarova, Maryna Ziuzina, Kharkiv, Ukraine 12:00–12:05 Correlations of clinical and neuroimaging features in small vessel disease due to arterial hypertension and cerebral atherosclerosis Mykola Petrenko, Kyiv, Ukraine 12:05–12:10 Impact of educational stress on the development of migraine in students Vita Shchebetenko, Kharkiv, Ukraine 12:10–12:30 Discussion and summarizing

56 57 Controversies in Neurology THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

PARTNERSHIP AND SUPPORT

GOLD SUPPORTERS

ТОВ РАНБАКСІ ФАРМАСЬЮТІКАЛС УКРАЇНА

УКРАЇНСЬКИЙ ЦЕНТР СНУ SILVER

MEDIA SUPPORT

BRONZE

58 59